ORLANDO, Fla., Sept. 7 /PRNewswire/ -- Daniel B. Yarosh, PhD, President and CEO AGI Dermatics, will deliver the keynote presentation at the 11th Annual Sunscreen Symposium today in Lake Buena Vista, FL. The multi-day gathering (September 6th-9th) of cosmetic chemists is sponsored by the Florida chapter of the Society of Cosmetic Chemists. Dr. Yarosh will present "Beyond Sunscreens: DNA Repair and Photoaging" to the more than 250 cosmetic chemists from around the U.S. and throughout the world who are scheduled to attend.
"Photoaging in skin is an extremely complex process and the genomic revolution has given us tools to understand UV-induced damage at the cellular level," said Dr. Yarosh. "Events such as the Sunscreen Symposium provide a forum in which we can share knowledge and ideas with colleagues, and further the sunscreen advancements around the world."
Dr. Yarosh, widely recognized as a pioneer in the science of DNA repair, is the author of more than 100 scientific papers and two dozen patents. He is an active participant in international photobiology societies and the New York biotechnology community.
AGI Dermatics founded by Dr. Yarosh in 1985, has emerged as a world leader in DNA repair technology for skin and is best known for developing Dimericine(R) (T4N5), a drug in testing for treating patients with skin cancers and pre-cancers. The U.S. Food & Drug Administration recently granted Fast Track designation for Dimericine for treatment of solar and ultraviolet photosensitivity in patients with Xeroderma Pigmentosum (XP), a rare genetic disorder that blocks the body's natural ability to repair DNA damage caused by ultraviolet light.
AGI Dermatics is also the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair.
AGI Dermatics is the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. www.agiderm.com
AGI DermaticsCONTACT: Liz Mefford, Liz.mefford@rprny.com, or Courtney McGeever,Courtney.mcgeever@rprny.com, both of Rpr Marketing Communications for AGIDermatics, +1-212-317-1462
Web site: http://www.agiderm.com/
